Abstract
Amphotericin B treatment during extracorporeal membrane oxygenation is at times necessary for the treatment of secondary fungemia or, less commonly, to treat a primary fungal infection. The impact of the extracorporeal circuit on the pharmacokinetics of amphotericin B have not been described in vivo. This case report describes the pharmacokinetics of amphotericin B in a patient receiving extracorporeal membrane oxygenation support for respiratory failure secondary to Blastomyces dermatitidis pneumonia. Amphotericin B concentrations were established and maintained at therapeutic levels with standard dosing despite the presence of a membrane oxygenator and intermittent replacement of extracorporeal circuit components. This suggests that no adjustments in the dosing of amphotericin B are necessary during extracorporeal membrane oxygenation.